10x Genomics TXG has actually been evaluated by 12 experts in the last 3 months, exposing a varied series of point of views from bullish to bearish.
The table listed below deals a condensed view of their current rankings, showcasing the altering beliefs over the previous 1 month and comparing them to the preceding months.
| Bullish | Rather Bullish | Indifferent | Rather Bearish | Bearish | |
|---|---|---|---|---|---|
| Overall Rankings | 5 | 3 | 4 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 1 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 4 | 2 | 3 | 0 | 0 |
Offering much deeper insights, experts have actually developed 12-month rate targets, suggesting a typical target of $15.5, together with a high price quote of $26.00 and a low price quote of $9.00. An unfavorable shift in belief appears as experts have actually reduced the typical rate target by 20.51%.
Checking Out Expert Rankings: An Extensive Summary
The analysis of current expert actions clarifies the understanding of 10x Genomics by economists. The following summary provides essential experts, their current assessments, and modifications to rankings and rate targets.
| Expert | Expert Company | Action Taken | Ranking | Existing Cost Target | Previous Cost Target |
|---|---|---|---|---|---|
| Kyle Mikson | Canaccord Genuity | Decreases | Buy | $ 15.00 | $ 18.00 |
| Rachel Vatnsdal | JP Morgan | Decreases | Neutral | $ 9.00 | $ 12.00 |
| Luke Sergott | Barclays | Decreases | Obese | $ 12.00 | $ 15.00 |
| Patrick Donnelly | Citigroup | Decreases | Buy | $ 15.00 | $ 20.00 |
| Tejas Sage | Morgan Stanley | Decreases | Obese | $ 26.00 | $ 28.00 |
| Luke Sergott | Barclays | Decreases | Obese | $ 15.00 | $ 18.00 |
| Kyle Mikson | Canaccord Genuity | Decreases | Buy | $ 18.00 | $ 20.00 |
| Patrick Donnelly | Citigroup | Decreases | Buy | $ 20.00 | $ 23.00 |
| Rachel Vatnsdal | JP Morgan | Decreases | Neutral | $ 12.00 | $ 14.00 |
| Dan Leonard | UBS | Decreases | Neutral | $ 14.00 | $ 20.00 |
| Daniel Arias | Stifel | Decreases | Buy | $ 18.00 | $ 21.00 |
| Mike Kratky | Leerink Partners | Decreases | Market Perform | $ 12.00 | $ 25.00 |
Secret Insights:
- Action Taken: Experts adjust their suggestions to altering market conditions and business efficiency. Whether they ‘Maintain’, ‘Raise’ or ‘Lower’ their position, it shows their reaction to current advancements connected to 10x Genomics. This details supplies a picture of how experts view the present state of the business.
- Ranking: Offering a detailed analysis, experts use qualitative evaluations, varying from ‘Outperform’ to ‘Underperform’. These rankings show expectations for the relative efficiency of 10x Genomics compared to the wider market.
- Cost Targets: Experts anticipate motions in rate targets, providing price quotes for 10x Genomics’s future worth. Taking a look at the present and previous targets provides insights into experts’ developing expectations.
For important insights into 10x Genomics’s market efficiency, think about these expert assessments together with vital monetary signs. Stay knowledgeable and make sensible choices utilizing our Rankings Table.
Stay up to date on 10x Genomics expert rankings.
If you have an interest in following small-cap stock news and efficiency you can begin by tracking it here.
Exploring 10x Genomics’s Background
10x Genomics Inc is a life science innovation business based in the United States. Its services consist of instruments, consumables, and software application for evaluating biological systems. The business’s incorporated services consist of instruments, consumables, and software application for evaluating biological systems at a resolution and scale that matches the intricacy of biology. Its item offerings consist of a Chromium platform making up microfluidic chips and associated consumables, Chromium X series, Visium and Xenium platforms, and others, which are mainly utilized for the research study of biological parts. Geographically, the business obtains optimum earnings from the United States and the rest from Americas (omitting the United States), Europe, Middle East and Africa, China, and Asia-Pacific (omitting China).
10x Genomics’s Economic Effect: An Analysis
Market Capitalization: With limited market capitalization, the business is placed listed below market averages. This shows a smaller sized scale relative to peers.
Income Development: 10x Genomics’s earnings development over a duration of 3M has actually dealt with obstacles. Since 31 March, 2025, the business experienced a profits decrease of around -6.14% This suggests a decline in the business’s top-line profits. As compared to rivals, the business experienced troubles, with a development rate lower than the average amongst peers in the Healthcare sector.
Net Margin: The business’s net margin is listed below market criteria, indicating prospective troubles in accomplishing strong success. With a net margin of -22.18%, the business might require to deal with obstacles in efficient expense control.
Return on Equity (ROE): 10x Genomics’s ROE is listed below market requirements, pointing towards troubles in effectively using equity capital. With an ROE of -4.85%, the business might experience obstacles in providing acceptable returns for investors.
Return on Possessions (ROA): 10x Genomics’s ROA is listed below market requirements, pointing towards troubles in effectively using properties. With an ROA of -3.77%, the business might experience obstacles in providing acceptable returns from its properties.
Financial Obligation Management: 10x Genomics’s debt-to-equity ratio is listed below the market average. With a ratio of 0.11, the business relies less on financial obligation funding, preserving a much healthier balance in between financial obligation and equity, which can be seen favorably by financiers.
The Core of Expert Rankings: What Every Financier Ought To Know
Expert rankings function as vital signs of stock efficiency, supplied by specialists in banking and monetary systems. These professionals vigilantly evaluate business monetary declarations, take part in teleconference, and engage with experts to create quarterly rankings for specific stocks.
Some experts release their forecasts for metrics such as development price quotes, profits, and earnings to supply extra assistance with their rankings. When utilizing expert rankings, it is essential to bear in mind that stock and sector experts are likewise human and are just providing their viewpoints to financiers.
If you wish to track which experts are surpassing others, you can see upgraded expert rankings along withanalyst success ratings in Benzinga Pro.
Which Stocks Are Experts Suggesting Now?
Benzinga Edge offers you immediate access to all significant expert upgrades, downgrades, and rate targets. Sort by precision, upside prospective, and more. Click on this link to remain ahead of the marketplace
This post was produced by Benzinga’s automatic material engine and examined by an editor.